CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
Summary Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells, is associated with melanoma tumor formation and poor prognosis in certain melanomas and several other tumor types. The comple...
Gespeichert in:
| Veröffentlicht in: | Pigment cell and melanoma research 2011-12, Vol.24 (6), p.1148-1157 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1157 |
|---|---|
| container_issue | 6 |
| container_start_page | 1148 |
| container_title | Pigment cell and melanoma research |
| container_volume | 24 |
| creator | Price, Matthew A. Colvin Wanshura, Leah E. Yang, Jianbo Carlson, Jennifer Xiang, Bo Li, Guiyuan Ferrone, Soldano Dudek, Arkadiusz Z. Turley, Eva A. McCarthy, James B. |
| description | Summary
Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells, is associated with melanoma tumor formation and poor prognosis in certain melanomas and several other tumor types. The complex mechanisms by which CSPG4 affects melanoma progression have started to be defined, in particular the association with other cell surface proteins and receptor tyrosine kinases (RTKs) and its central role in modulating the function of these proteins. CSPG4 is essential to the growth of melanoma tumors through its modulation of integrin function and enhanced growth factor receptor‐regulated pathways including sustained activation of ERK 1,2. This activation of integrin, RTK, and ERK1,2 function by CSPG4 modulates numerous aspects of tumor progression. CSPG4 expression has further been correlated to resistance of melanoma to conventional chemotherapeutics. This review outlines recent advances in our understanding of CSPG4‐associated cell signaling, describing the central role it plays in melanoma tumor cell growth, motility, and survival, and explores how modifying CSPG4 function and protein–protein interactions may provide us with novel combinatorial therapies for the treatment of advanced melanoma. |
| doi_str_mv | 10.1111/j.1755-148X.2011.00929.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3426219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>913719397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5779-40a0e9ee133b2cd75be4355e79e5fc31e83b2a439f53506ce048500bbb6513d73</originalsourceid><addsrcrecordid>eNqNUcFu1DAQjRCIlsIvIN-4NMGO4zg-gIRWsEUqpWyL4DZyspOtlyRObS_d_j0OWyK4MZcZed57M56XJITRjMV4vc2YFCJlRfU9yyljGaUqV9n-UXI8Nx7PtWRHyTPvt5SWVCj-NDnKc0oLxtlxcr24ulwWp0ST0QYcgtEdCTfo9Ii7YBoStNtgOCWtbkxngg7oSa87sxn0EMjo7Mah98YOxLakx04PttfPkyet7jy-eMgnydcP768XZ-n55-XHxbvztBFSqrSgmqJCZJzXebOWosaCC4FSoWgbzrCK77rgqhVc0LJBWlSC0rquS8H4WvKT5O1Bd9zVPa6buL_THYzO9Nrdg9UG_u0M5gY29ifwIi9zpqLAqwcBZ2936AP0xjfYxW-g3XlQjMsIU9Oo6oBsnPXeYTtPYRQmT2AL07lhOj1MnsBvT2AfqS__3nIm_jEhAt4cAHemw_v_FobLxadVrCI_PfCND7if-dr9gFJyKeDbxRKqi6uV5MUXWPFf-0qrkA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>913719397</pqid></control><display><type>article</type><title>CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Price, Matthew A. ; Colvin Wanshura, Leah E. ; Yang, Jianbo ; Carlson, Jennifer ; Xiang, Bo ; Li, Guiyuan ; Ferrone, Soldano ; Dudek, Arkadiusz Z. ; Turley, Eva A. ; McCarthy, James B.</creator><creatorcontrib>Price, Matthew A. ; Colvin Wanshura, Leah E. ; Yang, Jianbo ; Carlson, Jennifer ; Xiang, Bo ; Li, Guiyuan ; Ferrone, Soldano ; Dudek, Arkadiusz Z. ; Turley, Eva A. ; McCarthy, James B.</creatorcontrib><description>Summary
Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells, is associated with melanoma tumor formation and poor prognosis in certain melanomas and several other tumor types. The complex mechanisms by which CSPG4 affects melanoma progression have started to be defined, in particular the association with other cell surface proteins and receptor tyrosine kinases (RTKs) and its central role in modulating the function of these proteins. CSPG4 is essential to the growth of melanoma tumors through its modulation of integrin function and enhanced growth factor receptor‐regulated pathways including sustained activation of ERK 1,2. This activation of integrin, RTK, and ERK1,2 function by CSPG4 modulates numerous aspects of tumor progression. CSPG4 expression has further been correlated to resistance of melanoma to conventional chemotherapeutics. This review outlines recent advances in our understanding of CSPG4‐associated cell signaling, describing the central role it plays in melanoma tumor cell growth, motility, and survival, and explores how modifying CSPG4 function and protein–protein interactions may provide us with novel combinatorial therapies for the treatment of advanced melanoma.</description><identifier>ISSN: 1755-1471</identifier><identifier>EISSN: 1755-148X</identifier><identifier>DOI: 10.1111/j.1755-148X.2011.00929.x</identifier><identifier>PMID: 22004131</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Antigens - chemistry ; Antigens - metabolism ; CSPG4 ; Disease Progression ; HMW-MAA ; Humans ; melanoma ; Melanoma - pathology ; Melanoma - therapy ; melanoma chondroitin sulfate proteoglycan ; Molecular Targeted Therapy ; NG2 ; Proteoglycans - antagonists & inhibitors ; Proteoglycans - chemistry ; Proteoglycans - metabolism ; Signal Transduction ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; therapeutics</subject><ispartof>Pigment cell and melanoma research, 2011-12, Vol.24 (6), p.1148-1157</ispartof><rights>2011 John Wiley & Sons A/S</rights><rights>2011 John Wiley & Sons A/S.</rights><rights>2011 John Wiley & Sons A/S 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5779-40a0e9ee133b2cd75be4355e79e5fc31e83b2a439f53506ce048500bbb6513d73</citedby><cites>FETCH-LOGICAL-c5779-40a0e9ee133b2cd75be4355e79e5fc31e83b2a439f53506ce048500bbb6513d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1755-148X.2011.00929.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1755-148X.2011.00929.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22004131$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Price, Matthew A.</creatorcontrib><creatorcontrib>Colvin Wanshura, Leah E.</creatorcontrib><creatorcontrib>Yang, Jianbo</creatorcontrib><creatorcontrib>Carlson, Jennifer</creatorcontrib><creatorcontrib>Xiang, Bo</creatorcontrib><creatorcontrib>Li, Guiyuan</creatorcontrib><creatorcontrib>Ferrone, Soldano</creatorcontrib><creatorcontrib>Dudek, Arkadiusz Z.</creatorcontrib><creatorcontrib>Turley, Eva A.</creatorcontrib><creatorcontrib>McCarthy, James B.</creatorcontrib><title>CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma</title><title>Pigment cell and melanoma research</title><addtitle>Pigment Cell Melanoma Res</addtitle><description>Summary
Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells, is associated with melanoma tumor formation and poor prognosis in certain melanomas and several other tumor types. The complex mechanisms by which CSPG4 affects melanoma progression have started to be defined, in particular the association with other cell surface proteins and receptor tyrosine kinases (RTKs) and its central role in modulating the function of these proteins. CSPG4 is essential to the growth of melanoma tumors through its modulation of integrin function and enhanced growth factor receptor‐regulated pathways including sustained activation of ERK 1,2. This activation of integrin, RTK, and ERK1,2 function by CSPG4 modulates numerous aspects of tumor progression. CSPG4 expression has further been correlated to resistance of melanoma to conventional chemotherapeutics. This review outlines recent advances in our understanding of CSPG4‐associated cell signaling, describing the central role it plays in melanoma tumor cell growth, motility, and survival, and explores how modifying CSPG4 function and protein–protein interactions may provide us with novel combinatorial therapies for the treatment of advanced melanoma.</description><subject>Animals</subject><subject>Antigens - chemistry</subject><subject>Antigens - metabolism</subject><subject>CSPG4</subject><subject>Disease Progression</subject><subject>HMW-MAA</subject><subject>Humans</subject><subject>melanoma</subject><subject>Melanoma - pathology</subject><subject>Melanoma - therapy</subject><subject>melanoma chondroitin sulfate proteoglycan</subject><subject>Molecular Targeted Therapy</subject><subject>NG2</subject><subject>Proteoglycans - antagonists & inhibitors</subject><subject>Proteoglycans - chemistry</subject><subject>Proteoglycans - metabolism</subject><subject>Signal Transduction</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>therapeutics</subject><issn>1755-1471</issn><issn>1755-148X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUcFu1DAQjRCIlsIvIN-4NMGO4zg-gIRWsEUqpWyL4DZyspOtlyRObS_d_j0OWyK4MZcZed57M56XJITRjMV4vc2YFCJlRfU9yyljGaUqV9n-UXI8Nx7PtWRHyTPvt5SWVCj-NDnKc0oLxtlxcr24ulwWp0ST0QYcgtEdCTfo9Ii7YBoStNtgOCWtbkxngg7oSa87sxn0EMjo7Mah98YOxLakx04PttfPkyet7jy-eMgnydcP768XZ-n55-XHxbvztBFSqrSgmqJCZJzXebOWosaCC4FSoWgbzrCK77rgqhVc0LJBWlSC0rquS8H4WvKT5O1Bd9zVPa6buL_THYzO9Nrdg9UG_u0M5gY29ifwIi9zpqLAqwcBZ2936AP0xjfYxW-g3XlQjMsIU9Oo6oBsnPXeYTtPYRQmT2AL07lhOj1MnsBvT2AfqS__3nIm_jEhAt4cAHemw_v_FobLxadVrCI_PfCND7if-dr9gFJyKeDbxRKqi6uV5MUXWPFf-0qrkA</recordid><startdate>201112</startdate><enddate>201112</enddate><creator>Price, Matthew A.</creator><creator>Colvin Wanshura, Leah E.</creator><creator>Yang, Jianbo</creator><creator>Carlson, Jennifer</creator><creator>Xiang, Bo</creator><creator>Li, Guiyuan</creator><creator>Ferrone, Soldano</creator><creator>Dudek, Arkadiusz Z.</creator><creator>Turley, Eva A.</creator><creator>McCarthy, James B.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201112</creationdate><title>CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma</title><author>Price, Matthew A. ; Colvin Wanshura, Leah E. ; Yang, Jianbo ; Carlson, Jennifer ; Xiang, Bo ; Li, Guiyuan ; Ferrone, Soldano ; Dudek, Arkadiusz Z. ; Turley, Eva A. ; McCarthy, James B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5779-40a0e9ee133b2cd75be4355e79e5fc31e83b2a439f53506ce048500bbb6513d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Antigens - chemistry</topic><topic>Antigens - metabolism</topic><topic>CSPG4</topic><topic>Disease Progression</topic><topic>HMW-MAA</topic><topic>Humans</topic><topic>melanoma</topic><topic>Melanoma - pathology</topic><topic>Melanoma - therapy</topic><topic>melanoma chondroitin sulfate proteoglycan</topic><topic>Molecular Targeted Therapy</topic><topic>NG2</topic><topic>Proteoglycans - antagonists & inhibitors</topic><topic>Proteoglycans - chemistry</topic><topic>Proteoglycans - metabolism</topic><topic>Signal Transduction</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Price, Matthew A.</creatorcontrib><creatorcontrib>Colvin Wanshura, Leah E.</creatorcontrib><creatorcontrib>Yang, Jianbo</creatorcontrib><creatorcontrib>Carlson, Jennifer</creatorcontrib><creatorcontrib>Xiang, Bo</creatorcontrib><creatorcontrib>Li, Guiyuan</creatorcontrib><creatorcontrib>Ferrone, Soldano</creatorcontrib><creatorcontrib>Dudek, Arkadiusz Z.</creatorcontrib><creatorcontrib>Turley, Eva A.</creatorcontrib><creatorcontrib>McCarthy, James B.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pigment cell and melanoma research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Price, Matthew A.</au><au>Colvin Wanshura, Leah E.</au><au>Yang, Jianbo</au><au>Carlson, Jennifer</au><au>Xiang, Bo</au><au>Li, Guiyuan</au><au>Ferrone, Soldano</au><au>Dudek, Arkadiusz Z.</au><au>Turley, Eva A.</au><au>McCarthy, James B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma</atitle><jtitle>Pigment cell and melanoma research</jtitle><addtitle>Pigment Cell Melanoma Res</addtitle><date>2011-12</date><risdate>2011</risdate><volume>24</volume><issue>6</issue><spage>1148</spage><epage>1157</epage><pages>1148-1157</pages><issn>1755-1471</issn><eissn>1755-148X</eissn><abstract>Summary
Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells, is associated with melanoma tumor formation and poor prognosis in certain melanomas and several other tumor types. The complex mechanisms by which CSPG4 affects melanoma progression have started to be defined, in particular the association with other cell surface proteins and receptor tyrosine kinases (RTKs) and its central role in modulating the function of these proteins. CSPG4 is essential to the growth of melanoma tumors through its modulation of integrin function and enhanced growth factor receptor‐regulated pathways including sustained activation of ERK 1,2. This activation of integrin, RTK, and ERK1,2 function by CSPG4 modulates numerous aspects of tumor progression. CSPG4 expression has further been correlated to resistance of melanoma to conventional chemotherapeutics. This review outlines recent advances in our understanding of CSPG4‐associated cell signaling, describing the central role it plays in melanoma tumor cell growth, motility, and survival, and explores how modifying CSPG4 function and protein–protein interactions may provide us with novel combinatorial therapies for the treatment of advanced melanoma.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22004131</pmid><doi>10.1111/j.1755-148X.2011.00929.x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1755-1471 |
| ispartof | Pigment cell and melanoma research, 2011-12, Vol.24 (6), p.1148-1157 |
| issn | 1755-1471 1755-148X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3426219 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Antigens - chemistry Antigens - metabolism CSPG4 Disease Progression HMW-MAA Humans melanoma Melanoma - pathology Melanoma - therapy melanoma chondroitin sulfate proteoglycan Molecular Targeted Therapy NG2 Proteoglycans - antagonists & inhibitors Proteoglycans - chemistry Proteoglycans - metabolism Signal Transduction Skin Neoplasms - pathology Skin Neoplasms - therapy therapeutics |
| title | CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T04%3A24%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CSPG4,%20a%20potential%20therapeutic%20target,%20facilitates%20malignant%20progression%20of%20melanoma&rft.jtitle=Pigment%20cell%20and%20melanoma%20research&rft.au=Price,%20Matthew%20A.&rft.date=2011-12&rft.volume=24&rft.issue=6&rft.spage=1148&rft.epage=1157&rft.pages=1148-1157&rft.issn=1755-1471&rft.eissn=1755-148X&rft_id=info:doi/10.1111/j.1755-148X.2011.00929.x&rft_dat=%3Cproquest_pubme%3E913719397%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=913719397&rft_id=info:pmid/22004131&rfr_iscdi=true |